EOLS Share Price Performance
US$4.28
-10.76 (-71.54%)
71.8% undervalued intrinsic discount
US$15.17
Fair Value
Price US$4.28
AnalystConsensusTarget US$15.17
AnalystLowTarget US$10.00
AnalystHighTarget US$20.00
Fair ValueUS$15.17
Share Pricen/a
Evolus, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
EOLS Community Narratives
AN
Fair Value US$15.17 71.8% undervalued intrinsic discount
International Expansion And Pipeline Developments Will Reshape Aesthetics Markets
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$10 57.2% undervalued intrinsic discount
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$20 78.6% undervalued intrinsic discount
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
International Expansion And Pipeline Developments Will Reshape Aesthetics Markets
Key Takeaways Global expansion, new product launches, and strong loyalty engagement drive long-term revenue growth, diversification, and increased demand for both existing and future offerings. Operational realignment and automation support margin improvement and profitability while digital engagement and loyalty programs enhance market share and consumer retention.Read more
82
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$15.17
71.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
15.64% p.a.
Profit Margin
3.34%
Future PE
85.5x
Price in 2029
US$19.17
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
Catalysts About Evolus Evolus is a cash pay focused aesthetics company that markets neuromodulators and hyaluronic acid fillers to physicians and consumers. What are the underlying business or industry changes driving this perspective?Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
57.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
15.95% p.a.
Profit Margin
20.92%
Future PE
9.02x
Price in 2029
US$12.76
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
Catalysts About Evolus Evolus is a performance beauty company focused on cash pay injectable aesthetics, including neurotoxin and hyaluronic acid filler products. What are the underlying business or industry changes driving this perspective?Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
78.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
24.64% p.a.
Profit Margin
26.17%
Future PE
11.6x
Price in 2029
US$25.51
Trending Discussion
Recently Updated Narratives
AN
EOLS: Guidance Reset And 2028 Outlook Will Support Future Re Rating
Fair Value: US$15.17 71.8% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
Fair Value: US$10 57.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
Fair Value: US$20 78.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Evolus, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.90
- 66.63%
- -20.49%
- -506.9%
About EOLS
- Founded
- 2012
- Employees
- 329
- CEO
- WebsiteView website
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
